📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
232 analysed today
FollowTelegram
232
Today
149,633
All-time analysed
42,906
Positive
6,661
Negative
91,389
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
55 announcements match the current filters (relevance ≥ 5).
Sanofi Consumer Healthcare Appoints PwC as Statutory Auditor for 5-Year Term
Sanofi Consumer Healthcare India Limited has appointed Price Waterhouse & Co Chartered Accountants LLP (PwC) as its new Statutory Auditor. This appointment fills the casual vacancy created by the resignation of M/s. Kalyaniwalla & Mistry LLP on April 30, 2026. The Board has also recommended PwC for a full five-year term from 2026 to 2031, subject to shareholder approval at the upcoming Annual General Meeting. The transition to a Big Four affiliate firm is typically seen as a positive step for enhancing corporate governance and financial reporting credibility.
Key Highlights
Appointment of PwC to fill casual vacancy effective May 25, 2026, until the next AGM.
Recommended 5-year term for PwC starting from the 2026 AGM through to the 2031 AGM.
The change follows the resignation of previous auditors M/s. Kalyaniwalla & Mistry LLP on April 30, 2026.
PwC India network has over 120 Assurance Partners and 17 branch offices as of April 2026.
👀 What to Watch
Investors should view the appointment of a globally recognized audit firm as a positive governance move. No immediate action is required other than noting the change for future financial reporting cycles.
Sanofi Consumer Healthcare Statutory Auditor Resigns Due to Audit Fee Dispute
M/s. Kalyaniwalla & Mistry LLP has resigned as the statutory auditor of Sanofi Consumer Healthcare India Limited, effective April 30, 2026. The firm cited the commercial unviability of continuing the audit after the company declined a requested fee increase for FY 2026. The auditors were originally appointed for a five-year term ending in 2028. Notably, the outgoing auditors confirmed there are no other material concerns or issues with obtaining audit evidence.
Key Highlights
Statutory Auditor M/s. Kalyaniwalla & Mistry LLP resigned effective April 30, 2026.
The resignation follows the company's refusal to accommodate a fee increase requested on April 25, 2026.
The auditor was in the second year of a five-year term originally scheduled to run from 2024 to 2028.
Auditor confirmed no concerns regarding financial statements or inability to obtain audit evidence.
👀 What to Watch
Investors should monitor the appointment of a successor auditor to ensure a smooth transition. While auditor resignations can be a red flag, the explicit mention of a fee dispute suggests this is a commercial disagreement rather than a sign of financial irregularity.
Sanofi India Appoints Rahul Bhatnagar as Chairman; Succeeds Aditya Narayan
Sanofi India Limited has appointed Mr. Rahul Bhatnagar as the Chairman of its Board of Directors, effective April 30, 2026. He succeeds Mr. Aditya Narayan, who completed a distinguished 10-year tenure with the company. Mr. Bhatnagar, a Chartered Accountant and Wharton MBA, has been a member of the SIL Board since 2020 and brings extensive leadership experience from Nestlé, PepsiCo, and the Bharti Group. Additionally, the company announced the completion of Independent Director Mrs. Usha Thorat's tenure as of April 29, 2026.
Key Highlights
Mr. Rahul Bhatnagar appointed as Chairman of the Board effective April 30, 2026.
Outgoing Chairman Aditya Narayan concludes a decade-long tenure with the company.
Mr. Bhatnagar has served on SIL's Board since 2020 across Audit and Risk Management committees.
Independent Director Mrs. Usha Thorat's tenure ended on April 29, 2026.
The new Chairman brings global experience from leadership roles at Nestlé and PepsiCo.
👀 What to Watch
This is a planned leadership transition involving an experienced internal board member, suggesting continuity in governance. Investors should maintain their positions as this change is unlikely to disrupt short-term operations.
Sanofi Consumer Healthcare Q1 26: Revenue Up 33% to ₹2,292 MN, PAT Rises 36%
Sanofi Consumer Healthcare India (SCHIL) reported a strong Q1 2026 with total revenue reaching ₹2,292 million, a 33% year-on-year increase. Net profit for the quarter grew by 36% to ₹678 million, reflecting disciplined execution and market share gains. Domestic sales were up 15.5%, significantly aided by the relaunch of recalled products, while export sales surged 144% due to a low base effect. This performance marks a positive trajectory for the company following its demerger from Sanofi India in June 2024.
Key Highlights
Total Revenue grew 33% YoY to ₹2,292 million in Q1 2026
Net Profit (PAT) increased by 36% YoY to ₹678 million
Domestic sales grew by 15.5%, supported by product relaunches and market share gains
Export sales saw a significant 144% growth, primarily due to a low base in the previous year
Key brands like Allegra, DePURA, Avil, and Combiflam continue to drive the consumer healthcare portfolio
👀 What to Watch
The strong double-digit growth in both top-line and bottom-line suggests the demerged entity is scaling well; investors should monitor the sustainability of domestic volume growth. The successful relaunch of recalled products is a key positive catalyst for future quarters.
Sanofi India Declares ₹48 Final Dividend and Appoints Rahul Bhatnagar as New Chairman
Sanofi India concluded its 70th Annual General Meeting on April 29, 2026, where shareholders approved a final dividend of ₹48 per equity share, bringing the total dividend for FY 2025 to ₹123 per share. A significant leadership transition was announced, with Rahul Bhatnagar succeeding Aditya Narayan as Chairman effective April 30, 2026. The meeting also saw the appointment of Sudipta Chakraborty as Whole-time Director and the approval of material related party transactions with Sanofi-Aventis Singapore and Sanofi Healthcare India. The company reported no qualifications in its statutory audit for the financial year ended December 31, 2025.
Key Highlights
Confirmed total dividend of ₹123 per share for FY 2025, including a ₹75 interim and ₹48 final dividend.
Rahul Bhatnagar to take over as Chairman of the Board effective April 30, 2026.
Approved appointment of Ms. Sudipta Chakraborty as Whole-time Director and two new Independent Directors.
Ratified material related party transactions with Sanofi-Aventis Singapore Pte. Limited and Sanofi Healthcare India Private Limited.
Adopted audited financial statements for the year ended December 31, 2025, with no adverse auditor remarks.
👀 What to Watch
Investors should view the high dividend payout and the smooth leadership transition as signs of stability and strong governance. The stock remains an attractive option for dividend-seeking investors following the confirmation of the ₹123 total payout for the year.
Sanofi India Shareholders Approve ₹123 Total Dividend and New Board Appointments at 70th AGM
Sanofi India Limited's shareholders have approved all 11 resolutions at the 70th Annual General Meeting held on April 29, 2026. A key highlight is the approval of a ₹48 per share final dividend, which combined with the ₹75 interim dividend, brings the total payout for FY2025 to ₹123 per share. The meeting also confirmed the appointment of Sudipta Chakraborty as Whole-time Director and two new Independent Directors for five-year terms. Furthermore, material related-party transactions with Sanofi-Aventis Singapore were cleared by the members.
Key Highlights
Final dividend of ₹48 per share approved, resulting in a total FY2025 payout of ₹123 per share.
Appointment of Sudipta Chakraborty as Whole-time Director passed with 99.92% majority.
Two Independent Directors, Rajani Kesari and Siraj Azmat Chaudhry, appointed for 5-year terms until 2031.
All resolutions, including the adoption of FY2025 financial statements and related-party transactions, passed with requisite majority.
👀 What to Watch
Investors should note the high total dividend payout of ₹123 per share for FY2025, which continues Sanofi's trend of strong shareholder returns. The successful board appointments ensure governance stability and leadership continuity.
Sanofi India Appoints Rahul Bhatnagar as Chairman; Q1 Net Profit at ₹1,026 Million
Sanofi India has appointed Mr. Rahul Bhatnagar as the new Chairman of the Board effective April 30, 2026, following the completion of tenure for two independent directors. For the quarter ended March 31, 2026, the company reported a revenue of ₹4,723 million, a decline from ₹5,359 million in the same period last year. Net profit also saw a decrease to ₹1,026 million from ₹1,195 million YoY, primarily due to partnership transitions. However, the core insulin portfolio remains a bright spot, delivering a strong 19% year-on-year growth.
Key Highlights
Mr. Rahul Bhatnagar appointed as Chairman of the Board effective April 30, 2026.
Q1 2026 revenue from operations stood at ₹4,723 million, down 11.8% from ₹5,359 million in Q1 2025.
Net profit for the quarter decreased to ₹1,026 million compared to ₹1,195 million in the previous year.
Insulin portfolio achieved double-digit growth of 19% YoY and 14% sequentially.
Tenure of Independent Directors Mr. Aditya Narayan and Mrs. Usha Thorat ends on April 29, 2026.
👀 What to Watch
Investors should watch for the stabilization of partnership transitions which impacted this quarter's revenue. The continued double-digit growth in the insulin segment suggests strong market positioning in core therapeutic areas.
Sanofi India Q1 PAT at ₹1,026M; Rahul Bhatnagar Appointed Chairman as Insulin Sales Grow 19% YoY
Sanofi India reported a Profit After Tax of ₹1,026 million for the quarter ended March 31, 2026, showing a strong sequential recovery from the previous quarter's ₹617 million. While revenue of ₹4,723 million was lower than the same period last year (₹5,359 million), the company's core insulin portfolio showed significant momentum with 19% year-on-year growth. The board also underwent a leadership transition, appointing Rahul Bhatnagar as the new Chairman effective April 30, 2026. Management noted that while partnership transitions impacted overall quarterly results, export sales are beginning to stabilize.
Key Highlights
Net Profit for Q1 2026 stood at ₹1,026 million, representing a 66% sequential increase from Q4 2025.
Revenue from operations reached ₹4,723 million, a decline of 11.8% compared to ₹5,359 million in Q1 2025.
The Insulin portfolio delivered exceptional performance with 19% YoY and 14% QoQ growth.
Rahul Bhatnagar appointed as Chairman of the Board effective April 30, 2026, following the completion of tenures of two independent directors.
Basic and diluted Earnings Per Share (EPS) for the quarter was ₹44.55, down from ₹51.89 in the previous year's quarter.
👀 What to Watch
Investors should monitor the impact of ongoing partnership transitions on revenue and margins, while keeping a close eye on the continued growth of the high-margin insulin segment. The leadership change appears to be a planned transition, but the year-on-year decline in top-line performance requires a cautious outlook.
Sanofi India Q1 Net Profit Dips 14% YoY to ₹1,026 Mn; Insulin Portfolio Grows 19%
Sanofi India reported a 14% year-on-year decline in net profit to ₹1,026 million for the quarter ended March 31, 2026, as revenue was impacted by partnership transitions. Revenue from operations fell 11.8% YoY to ₹4,723 million, though it showed a healthy sequential recovery of 12.5% compared to the previous quarter. The company's core insulin portfolio remains a standout performer, registering 19% YoY growth and 14% QoQ growth. The board also announced leadership changes, appointing Rahul Bhatnagar as the new Chairman effective April 30, 2026.
Key Highlights
Net Profit for the quarter stood at ₹1,026 million, down 14.1% compared to ₹1,195 million in the previous year's corresponding quarter.
Revenue from operations decreased to ₹4,723 million from ₹5,359 million YoY, primarily due to transactions relating to partnership transitions.
The Insulin portfolio delivered robust growth of 19% YoY and 14% QoQ, demonstrating strong equity in the diabetes segment.
Profit before tax (PBT) showed a significant sequential improvement, rising 66% from ₹830 million in Q4 2025 to ₹1,379 million.
Mr. Rahul Bhatnagar has been appointed as the Chairman of the Board effective April 30, 2026, following the completion of tenures of two independent directors.
👀 What to Watch
Investors should focus on the strong sequential recovery and the resilience of the insulin portfolio despite the temporary impact of partnership transitions. The leadership change and committee reconstitutions suggest a period of governance transition alongside business model adjustments.
Sanofi India Q1 PAT Drops 14% YoY to ₹103 Cr; Rahul Bhatnagar Appointed Chairman
Sanofi India reported a 14.1% YoY decline in Net Profit to ₹1,026 million for the quarter ended March 31, 2026, while revenue fell 11.9% YoY to ₹4,723 million. The performance was primarily impacted by transitions in business partnerships, though the core insulin portfolio showed strong resilience with 19% YoY growth. Sequentially, the company demonstrated a sharp recovery with PAT rising 66.3% compared to the December 2025 quarter. Additionally, the board has appointed Rahul Bhatnagar as the new Chairman effective April 30, 2026.
Key Highlights
Revenue from operations decreased 11.9% YoY to ₹4,723 million from ₹5,359 million.
Net Profit (PAT) stood at ₹1,026 million, down 14.1% YoY but up 66.3% on a QoQ basis.
Insulin portfolio delivered robust growth of 19% YoY and 14% over the previous quarter.
Rahul Bhatnagar appointed as Chairman of the Board following the completion of tenure of previous directors.
Earnings Per Share (EPS) for the quarter was ₹44.55, down from ₹51.89 in the same period last year.
👀 What to Watch
Investors should monitor the stabilization of partnership transitions which impacted top-line growth this quarter. The strong sequential recovery and leadership change suggest a period of consolidation; long-term holders should focus on the insulin portfolio's continued dominance.
Sanofi Consumer Healthcare Q1 PAT Rises 35.6% YoY to ₹67.8 Cr; Revenue Up 32.8%
Sanofi Consumer Healthcare India reported a strong year-on-year performance for the quarter ended March 31, 2026, with net profit rising 35.6% to ₹678 million. Revenue from operations grew 32.8% YoY to ₹2,292 million, primarily driven by a 15.5% growth in domestic sales following the successful relaunch of key brands like Allegra and Combiflam. While YoY growth is robust, revenue saw a sequential decline of 8.7% compared to the December 2025 quarter. The company maintains healthy margins with Profit Before Tax (PBT) reaching ₹907 million.
Key Highlights
Revenue from operations increased 32.8% YoY to ₹2,292 million from ₹1,726 million.
Net Profit (PAT) grew 35.6% YoY to ₹678 million compared to ₹500 million in the year-ago period.
Domestic sales grew by 15.5% YoY, aided by the relaunch of Allegra Suspension, Combiflam Suspension, and Depura Kids.
Export sales witnessed a significant jump of 144.4% YoY, though on a lower base.
Earnings Per Share (EPS) improved to ₹29.44 from ₹21.69 in the same quarter last year.
👀 What to Watch
Investors should view the strong YoY growth as a sign of successful brand recovery following previous product recalls. The stock remains a watch for steady growth in the consumer healthcare segment, though sequential revenue dips should be monitored for seasonality.
Sanofi Consumer Healthcare Shareholders Approve Key RPTs and MD Remuneration
Sanofi Consumer Healthcare India Limited (SANOFICONR) has announced the successful passage of four key resolutions via postal ballot, all receiving over 99.9% shareholder approval. The resolutions include material related party transactions with Opella Healthcare entities and the establishment of remuneration limits for Non-Executive Directors. Crucially, shareholders approved an amendment to Managing Director Himanshu Bakshi's remuneration to enable his participation in the company's incentive plan. These approvals facilitate operational continuity and align leadership incentives with business performance.
Key Highlights
Material related party transactions with Opella Healthcare India and International SAS approved with over 99.94% votes in favor.
Remuneration limits for Non-Executive Directors passed with a near-unanimous 99.99% majority.
Amendment to MD Himanshu Bakshi's remuneration for incentive plan participation approved by 99.98% of voters.
The voting process involved 50,742 shareholders on record as of March 20, 2026.
👀 What to Watch
Investors should take note of the strong shareholder support for management's compensation structure and operational agreements. The alignment of the Managing Director's pay with incentive plans is a positive governance signal for long-term performance.
Sanofi India Announces 70th AGM and Final Dividend of Rs. 48 Per Share
Sanofi India Limited has scheduled its 70th Annual General Meeting (AGM) for April 29, 2026, to discuss the financial year ended December 31, 2025. The company has recommended a final dividend of Rs. 48 per share, with the record date set for April 22, 2026. Shareholders must update their KYC and bank details by April 15, 2026, to ensure seamless dividend credit. Additionally, a special regulatory window is open until February 2027 for the dematerialization of physical shares held before April 2019.
Key Highlights
Final dividend of Rs. 48 per share announced for the financial year ended December 31, 2025
Record date for dividend eligibility and e-voting cut-off is April 22, 2026
70th Annual General Meeting scheduled for April 29, 2026, via Video Conferencing
Dividend payment to be completed on or before May 28, 2026
Special one-year window (Feb 2026 - Feb 2027) for transfer and demat of old physical securities
👀 What to Watch
Investors should ensure they hold shares by the record date of April 22, 2026, to qualify for the Rs. 48 dividend. Physical shareholders should utilize the special window to dematerialize their holdings before February 2027.
Sanofi India Announces Rs 48 Final Dividend; Sets Record Date for April 22, 2026
Sanofi India has recommended a final dividend of Rs 48 per equity share for the financial year ended December 31, 2025. The company has fixed April 22, 2026, as the record date to determine shareholder eligibility for this payout. Investors are required to submit tax-related declarations by April 15, 2026, to ensure the correct Tax Deduction at Source (TDS) rate is applied. Additionally, the company has transitioned to exclusively electronic payment modes, discontinuing physical dividend warrants.
Key Highlights
Final dividend of Rs 48 per equity share recommended for the financial year ended December 31, 2025.
Record date for dividend eligibility is April 22, 2026, with a document submission deadline of April 15, 2026.
Standard TDS of 10% applies to resident individuals with valid PAN, while 20% applies if PAN is missing.
No TDS will be deducted for resident individual shareholders if the total dividend does not exceed Rs 10,000.
Physical dividend warrants are discontinued; all payments will be made via electronic modes like NEFT/RTGS.
👀 What to Watch
Shareholders should ensure their PAN and bank account details are updated with their Depository Participant or RTA before the record date. Eligible investors should submit Form 15G/15H or DTAA documents by April 15 to minimize tax withholding.
Sanofi India Receives Govt Approval for Deepak Arora as Managing Director for 3-Year Term
Sanofi India Limited has received formal approval from the Central Government for the appointment of Mr. Deepak Arora as the Managing Director. The appointment is valid for a period of 3 years, effective retrospectively from October 27, 2025. This regulatory clearance follows the company's initial board intimations made in October and December 2025. The approval ensures leadership continuity and fulfills statutory requirements for the top executive position.
Key Highlights
Central Government approval received on April 1, 2026, for the appointment of Mr. Deepak Arora.
The appointment as Managing Director is for a fixed tenure of 3 years.
The term is effective from October 27, 2025, providing retrospective leadership validation.
The approval concludes a regulatory process initiated via board resolutions in late 2025.
👀 What to Watch
Investors should view this as a positive administrative milestone that ensures leadership stability. No immediate action is required as the appointment was previously anticipated and is now formally ratified.
Sanofi India Receives Govt Approval for Deepak Arora as MD for 3-Year Term
Sanofi India Limited has received formal approval from the Central Government for the appointment of Mr. Deepak Arora as the Managing Director. The appointment is valid for a period of three years, effective retrospectively from October 27, 2025. This regulatory clearance follows the company's initial board decisions and shareholder communications made in late 2025. The confirmation ensures leadership stability and completes the necessary statutory requirements for the top executive role.
Key Highlights
Central Government approval received on April 1, 2026, for the Managing Director position.
Mr. Deepak Arora appointed for a fixed tenure of 3 years.
The appointment is effective from October 27, 2025, ensuring continuity in leadership.
The approval follows previous company intimations dated October 27 and December 18, 2025.
👀 What to Watch
Investors should take note of the finalized leadership structure which provides regulatory certainty. No immediate portfolio changes are required as this is a procedural confirmation of a previously announced appointment.
Sanofi Consumer Healthcare Reports 21% Revenue Growth and 62.5% ROCE in First Investor Meet
Sanofi Consumer Healthcare India Limited (SCHIL) detailed its strategic transition to a standalone 'Fast Moving Consumer Health' entity following its demerger. For FY2025, the company reported a turnover of approximately ₹880 crore, representing a 21% revenue growth and a 33% increase in PAT. Management is aggressively pivoting from a prescription-only model to a brand-led consumer model, increasing advertising and promotion spends from low single digits to mid-teens. The company maintains a high-quality balance sheet with an operating profit margin of 37% and a robust ROCE of 62.5%.
Key Highlights
Achieved ₹880 crore turnover with a 33% year-on-year increase in Profit After Tax (PAT).
Reported a high Return on Capital Employed (ROCE) of 62.5% and operating profit margins of 37%.
Increased brand investment (A&P) to mid-teen percentages to drive self-choice consumer growth.
Core brands like Avil, Allegra, and Combiflam maintain top 5 positions in their respective categories.
Successfully completed product relaunches following precautionary quality recalls, restoring market leadership.
👀 What to Watch
Investors should monitor the company's ability to sustain high margins while scaling marketing spends in the competitive consumer health space. The high ROCE and strong brand legacy make it a premium play in the Indian healthcare sector.
Sanofi India Sets Record Date for ₹48 Final Dividend; Appoints Siraj Chaudhry to Board
Sanofi India has announced April 22, 2026, as the record date for its final dividend of ₹48 per equity share for the financial year ended December 31, 2025. The company will hold its 70th Annual General Meeting on April 29, 2026, to seek shareholder approval for this payout. Additionally, the board has appointed Siraj Azmat Chaudhry, former Chairman of Cargill India, as an Independent Director for a five-year term. This leadership addition brings significant FMCG and agricultural sector expertise to the board.
Key Highlights
Final dividend of ₹48 per equity share (face value ₹10) recommended for FY ended Dec 31, 2025.
Record date for dividend eligibility fixed as April 22, 2026; Book closure from April 23 to April 29, 2026.
Appointment of Siraj Azmat Chaudhry as Independent Director for a 5-year term starting April 1, 2026.
70th Annual General Meeting scheduled for April 29, 2026, via Video Conferencing.
Mr. Chaudhry brings over 35 years of experience, including leadership roles at Cargill India and various industry bodies.
👀 What to Watch
Investors interested in the ₹48 dividend should ensure they hold the stock before the ex-dividend date (typically one day prior to the April 22 record date). The high-profile board appointment is a positive signal for the company's governance and strategic oversight.
Sanofi India Sets April 22 as Record Date for ₹48 Final Dividend; Appoints New Director
Sanofi India has finalized April 22, 2026, as the record date for its final dividend of ₹48 per equity share for the financial year ended December 31, 2025. The dividend payment is subject to shareholder approval at the 70th Annual General Meeting (AGM) scheduled for April 29, 2026. In a significant management update, the company has also appointed Mr. Siraj Azmat Chaudhry, former Chairman of Cargill India, as an Independent Director for a five-year term. The book closure for the dividend and AGM will occur from April 23 to April 29, 2026.
Key Highlights
Final dividend of ₹48 per equity share of face value ₹10 recommended for FY2025.
Record date for dividend eligibility fixed as April 22, 2026.
70th Annual General Meeting (AGM) to be held on April 29, 2026.
Appointment of Mr. Siraj Azmat Chaudhry as Independent Director for a 5-year term starting April 1, 2026.
Book closure period for dividend and AGM set from April 23 to April 29, 2026.
👀 What to Watch
Investors looking to benefit from the ₹48 dividend should ensure they hold the stock before the ex-dividend date (typically one day prior to the April 22 record date). The addition of an experienced industry leader like Siraj Chaudhry to the board is a positive governance signal.
Sanofi India Sets Record Date for ₹48 Dividend and Appoints New Independent Director
Sanofi India has scheduled its 70th Annual General Meeting for April 29, 2026, to seek shareholder approval for various resolutions. The company has fixed April 22, 2026, as the record date for the final dividend of ₹48 per equity share for the financial year ended December 31, 2025. Furthermore, the board has appointed Mr. Siraj Azmat Chaudhry, former Chairman of Cargill India, as an Independent Director for a five-year term. These announcements provide clarity on the dividend payout timeline and demonstrate a strengthening of the company's governance framework.
Key Highlights
Final dividend of ₹48 per equity share of ₹10 each recommended for the year ended Dec 31, 2025.
Record date for dividend eligibility is fixed as Wednesday, April 22, 2026.
70th Annual General Meeting (AGM) scheduled for April 29, 2026, at 3:30 p.m. IST.
Appointment of Mr. Siraj Azmat Chaudhry as Independent Director for a 5-year term starting April 1, 2026.
Mr. Chaudhry brings 35 years of experience, including leading Cargill India to a ₹5,000 crore entity.
👀 What to Watch
Investors interested in the ₹48 per share dividend should ensure they hold the stock by the record date of April 22, 2026. The appointment of a high-profile industry veteran to the board is a positive sign for long-term strategic oversight.
